Details

Blood and Marrow Transplantation Long Term Management


Blood and Marrow Transplantation Long Term Management

Survivorship after Transplant
2. Aufl.

von: Bipin N. Savani, Andre Tichelli

139,99 €

Verlag: Wiley-Blackwell
Format: EPUB
Veröffentl.: 16.03.2021
ISBN/EAN: 9781119612735
Sprache: englisch
Anzahl Seiten: 464

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

<b>Blood and Marrow Transplantation Long Term Management</b> <p>Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT, to the point where HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients.<p>The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated.<p>These patients have increased risks for a variety of late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring and management of long complications after HCT for this patient population. As HCT survivorship increases, the focus of care has shifted to the identification and treatment of long-term complications that may affect quality of life and long-term morbidity and mortality.<p>Preventive care as well as early detection and treatments are important aspects to reducing morbidity and mortality in long-term survivors after allo-HCT. This second edition, <i>Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant</i>, provides up-to-date information about diagnosis, screening, treatment, and long-term surveillance of long-term survivors after HCT.
<p>Foreword by <i>Professor John Barrett</i> vii</p> <p>Foreword by <i>Professor John Goldman</i> viii</p> <p>List of Contributors ix</p> <p><b>Section 1 Late effects concepts 1</b></p> <p>1 Introduction to long‐term survivorship after hematopoietic cell transplantation 3<br /><i>Bipin N. Savani and André Tichelli</i></p> <p>2 International Blood and Marrow Registries: trends on long‐term data collection 6<br /><i>Rachel Phelan, Jakob R. Passweg, Helen Baldomero, Minako Iida, Yoshiko Atsuta, Shinichiro Okamoto, Mahmoud Aljurf, Feras Alfraih, and Bronwen E. Shaw</i></p> <p>3 Long‐term follow‐up program and transplant clinic setup 14<br /><i>André Tichelli, Bipin N. Savani, Shahrukh K. Hashmi, Navneet S. Majhail, and Alicia Rov</i><i>ó</i></p> <p>4 Telemedicine in patient care of long‐term transplant survivors 25<br /><i>Catherine J. Lee, Mihkaila Wickline, and Mary E.D. Flowers</i></p> <p>5 Long‐term follow‐up calendar 33<br /><i>André Tichelli, Bipin N. Savani, Shahrukh K. Hashmi, Navneet S. Majhail, and Alicia Rov</i><i>ó</i></p> <p>6 Late effects post‐allogeneic hematopoietic stem cell transplantation 38<br /><i>Shahrukh K. Hashmi and Yoshihiro Inamoto</i></p> <p>7 Late effects post‐autologous hematopoietic stem cell transplantation 47<br /><i>Rajshekhar Chakraborty and Betty K. Hamilton</i></p> <p>8 Long‐term follow‐up of children 58<br /><i>Paul A. Carpenter</i></p> <p>9 Graft‐versus‐host disease and late effects after hematopoietic stem cell transplantation 73<br /><i>David Michonneau, Aurélien Sutra del Galy, and Gérard Socié</i></p> <p>10 Screening and prevention guidelines for hematopoietic cell transplant survivors 80<br /><i>Neel S. Bhatt, J. Douglas Rizzo, and Navneet S. Majhail</i></p> <p>11 Biology of survivorship after blood or marrow transplantation 92<br /><i>Smita Bhatia</i></p> <p><b>Section 2 Specific late effects 101</b></p> <p>12 Second malignancies 103<br /><i>Aurélien Sutra del Galy, David Michonneau, and Gérard Socié</i></p> <p>13 Anti‐infective prophylaxis, immunization and prevention of late infectious complications 112<br /><i>Per Ljungman</i></p> <p>14 Seasonal respiratory viral infections 119<br /><i>Nosha Farhadfar, Zeina Al‐Mansour, and John R. Wingard</i></p> <p>15 Monitoring and management of hepatitis B, C, and HIV infection before and after transplantation 132<br /><i>Enric Carreras and Montserrat Rovira</i></p> <p>16 Skin chronic GVHD 140<br /><i>Attilio Olivieri, Anna Campanati, Gaia Goteri, and Andrea Bacigalupo</i></p> <p>17 Ocular complications 166<br /><i>Alicia Rov</i><i>ó, André Tichelli, and Yoshihiro Inamoto</i></p> <p>18 Management of oral and dental complications 176<br /><i>Hildegard T. Greinix</i></p> <p>19 Thyroid disease: monitoring and management guidelines 183<br /><i>Juliana Matthews, Leslee Matheny, and Shubhuda Jagasia</i></p> <p>20 Pretransplant considerations in gender, reproductive, and sexual health 189<br /><i>Dana Shanis, Jeanne Murphy, Kate Debiec, Betty K. Hamilton, Shawna Boyle, and Pamela Stratton</i></p> <p>21 Posttransplant Considerations in Gender, Reproductive, and Sexual Health 198<br /><i>Jeanne Murphy, Dana Shanis, Kate Debiec, Betty K. Hamilton, Shawna Boyle, and Pamela Stratton</i></p> <p>22 Fertility issues, fertility preservation, and pregnancy outcome in long‐term survivors 211<br /><i>Alicia Rov</i><i>ó, Alison W. Loren, André Tichelli, and Nina Salooja</i></p> <p>23 Sexual Dysfunction in Long‐Term Survivors 221<br /><i>Rebecca L. Hunter, Sarah Thilges, Janna Gordon, Kristy Luke, Karla Cavazos, Emilee Moeke, Colleen Bruen, and Sunita Nathan</i></p> <p>24 Late non‐infectious pulmonary complications 231<br /><i>Ayman O. Soubani</i></p> <p>25 Cardiac and arterial complications 241<br /><i>Alicia Rov</i><i>ó and André Tichelli</i></p> <p>26 Cardiovascular risk factors 251<br /><i>Kimberley Doucette and Minoo Battiwalla</i></p> <p>27 Gastrointestinal complications 260<br /><i>Sumona Bhattacharya, Steven Pavletic, and Theo Heller</i></p> <p>28 Hepatic Complications 271<br /><i>Christy Ann L. Gilman, Christopher Koh, Steven Pavletic, and Theo Heller</i></p> <p>29 Renal complications 278<br /><i>Insara Jaffer Sathick and Sangeeta Hingorani</i></p> <p>30 Posttransplantation bone disease: prevalence, surveillance, prevention, and management 287<br /><i>Christine N. Duncan</i></p> <p>31 Late neurologic complications 300<br /><i>Enrico Maffini</i></p> <p>32 Neurocognitive dysfunction 312<br /><i>David Buchbinder and Angela Scherwath</i></p> <p>33 Psychological Distress 330<br /><i>Anna Barata, Aasha I. Hoogland, and Heather S. L. Jim</i></p> <p>34 Evaluation and management of fatigue in survivors of allogeneic hematopoietic stem cell transplantation 337<br /><i>Sandra A. Mitchell</i></p> <p>35 Social Issues 349<br /><i>Sanghee Hong and Navneet S. Majhail</i></p> <p>36 Health‐related quality of life in adult and pediatric survivors 355<br /><i>Sandra A. Mitchell, Lori Wiener, Jenny Hoag, Abigail Fry, and Margaret F. Bevans</i></p> <p><b>Section 3 Supportive care and patients reported outcomes 381</b></p> <p>37 Immunosuppressive agents and monitoring in long‐term survivors 383<br /><i>Kathryn A. Culos and Katie S. Gatwood</i></p> <p>38 Nutritional support and nutritional supplementation 393<br /><i>Shigeo Fuji</i></p> <p>39 Daily routines and healthy lifestyle guidelines 397<br /><i>Melissa Logue</i></p> <p>40 Prevalent psychosocial adjustment issues and solutions: lifestyle and social challenges 402<br /><i>Katrina M. Stokes</i></p> <p>41 Complementary and alternative medicine in HSCT 406<br /><i>Ibrahim N. Muhsen, Bipin N. Savani,, and Shahrukh K. Hashmi</i></p> <p>42 Impact of adherence in outcome of long‐term survivors 413<br /><i>Corien Eeltink and Annika Kisch</i></p> <p>43 Prominent role of allied health professionals 418<br /><i>Catherine E. Lucid</i></p> <p>44 Patient reported outcomes 420<br /><i>Hél</i><i>ène Schoemans</i></p> <p>45 Caregivers of long‐term survivors 428<br /><i>Angela Moreschi Woods</i></p> <p>46 Patient’s perspective: memoir of a recovered lymphomaniac 434<br /><i>Michael Brown</i></p> <p>Appendix 1 Commonly used transplant‐related medications in long‐term survivors 442<br /><i>Kathryn A. Culos and Katie S. Gatwood</i></p> <p>Appendix 2 The eGVHD App 445<br /><i>Hél</i><i>ène Schoemans</i></p> <p>Index 448</p>
<p><b>About the Editors</b></p><p><b>Bipin N. Savani</b> is Professor of Medicine and Director of Long-Term Transplant and Survivorship Clinic at Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.</p><p><b>André Tichelli</b> is Professor Emeritus of Hematology, Division of Hematology, University Hospital Basel, Switzerland.</p>
<p>Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT, to the point where HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients.</p><p>The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated.</p><p>These patients have increased risks for a variety of late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring and management of long complications after HCT for this patient population. As HCT survivorship increases, the focus of care has shifted to the identification and treatment of long-term complications that may affect quality of life and long-term morbidity and mortality.</p><p>Preventive care as well as early detection and treatments are important aspects to reducing morbidity and mortality in long-term survivors after allo-HCT. This second edition, <i>Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant</i>, provides up-to-date information about diagnosis, screening, treatment, and long-term surveillance of long-term survivors after HCT. </p>

Diese Produkte könnten Sie auch interessieren:

Biomedical Imaging
Biomedical Imaging
von: Reiner Salzer
PDF ebook
120,99 €
Clinical Reasoning in Occupational Therapy
Clinical Reasoning in Occupational Therapy
von: Linda Robertson
PDF ebook
38,99 €
Clinical Reasoning in Occupational Therapy
Clinical Reasoning in Occupational Therapy
von: Linda Robertson
EPUB ebook
38,99 €